Clinical Trial Update: A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications. [Phase 2]

View source ↗

Summary

A 48-week Open Label study evaluated the efficacy and safety of AMONDYS 45, EXONDYS 51, and VYONDYS 53 in Duchenne muscular dystrophy patients with eligible dup…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• AMONDYS 45 (Casimersen)
• EXONDYS 51 (eteplirsen)
• VYONDYS 53 (golodirsen)

Snippet

Sponsor: Kevin Flanigan | Conditions: Duchenne Muscular Dystrophy | Phase 2 | Status: COMPLETED | Results posted: 2023-10-12